Acute Myeloid Leukemia Clinical Trials in Los Angeles, California
25 recruitingLos Angeles, California
Showing 1–20 of 25 trials
Recruiting
Phase 2
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
National Cancer Institute (NCI)147 enrolled218 locationsNCT06317649
Recruiting
Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
National Cancer Institute (NCI)153 enrolled175 locationsNCT05554393
Recruiting
Phase 2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm+1 more
National Cancer Institute (NCI)335 enrolled216 locationsNCT05554406
Recruiting
Phase 2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled331 locationsNCT05564390
Recruiting
Phase 1Phase 2
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMixed Phenotype Acute Leukemia+2 more
Syndax Pharmaceuticals447 enrolled57 locationsNCT04065399
Recruiting
Phase 2Phase 3
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+1 more
Taiho Oncology, Inc.316 enrolled73 locationsNCT04256317
Recruiting
Phase 1
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Seagen, a wholly owned subsidiary of Pfizer178 enrolled54 locationsNCT04227847
Recruiting
Phase 1
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Acute Myeloid LeukemiaMyeloid SarcomaAcute Myeloid Leukemia, in Relapse+7 more
Kura Oncology, Inc.420 enrolled44 locationsNCT05735184
Recruiting
Phase 3
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Acute Myeloid Leukemia (AML)
Kura Oncology, Inc.1,300 enrolled29 locationsNCT07007312
Recruiting
Phase 2
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
Acute Myeloid Leukemia
Stemline Therapeutics, Inc.83 enrolled32 locationsNCT06456463
Recruiting
Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Acute Myeloid Leukemia
Children's Oncology Group1,186 enrolled205 locationsNCT04293562
Recruiting
Phase 1Phase 2
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome+5 more
PedAL BCU, LLC960 enrolled182 locationsNCT04726241
Recruiting
Phase 3
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Adult Acute Myeloid Leukemia
Priothera SAS366 enrolled108 locationsNCT05429632
Recruiting
Phase 1
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome (MDS)Relapsed/Refractory Acute Myeloid Leukemia (AML)
Cullinan Therapeutics Inc.60 enrolled11 locationsNCT05143996
Recruiting
Phase 1
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Relapsed/Refractory Acute Myeloid Leukemia
SystImmune Inc.120 enrolled14 locationsNCT06714591
Recruiting
Phase 1Phase 2
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Beat AML, LLC3,000 enrolled19 locationsNCT03013998
Recruiting
Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
Acute Myeloid Leukemia
University of Southern California250 enrolled1 locationNCT03921047
Recruiting
Phase 1
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Acute Myeloid LeukemiaAcute LeukemiaAML+9 more
Kura Oncology, Inc.171 enrolled44 locationsNCT06001788
Recruiting
Phase 1Phase 2
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAdvanced Malignant Neoplasm+4 more
Kura Oncology, Inc.263 enrolled56 locationsNCT04067336
Recruiting
Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854